Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone609-662-2000
Debt
Current Ratio9.12
Quick Ratio9.03
Price-To-Earnings
Sales & Book Value
Annual Sales$36.93 million
Price / Sales61.46
Price / Cash FlowN/A
Price / Book5.66
Profitability
Net Income$-284,000,000.00
Net Margins-463.82%
Return on Assets-30.40%
Miscellaneous
Employees325
OptionableOptionable
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.04. The biopharmaceutical company earned $20.60 million during the quarter, compared to analysts' expectations of $23.56 million. Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. Amicus Therapeutics's revenue for the quarter was up 89.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.41) EPS. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What guidance has Amicus Therapeutics issued on next quarter's earnings?
Amicus Therapeutics updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160-180 million, compared to the consensus revenue estimate of $173.18 million.
What price target have analysts set for FOLD?
6 brokerages have issued 12-month price objectives for Amicus Therapeutics' shares. Their predictions range from $12.00 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 66.8% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.
What is the consensus analysts' recommendation for Amicus Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.
Has Amicus Therapeutics been receiving favorable news coverage?
News headlines about FOLD stock have trended somewhat positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amicus Therapeutics earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 28,269,257 shares, an increase of 3.6% from the December 14th total of 27,289,481 shares. Based on an average daily volume of 2,766,676 shares, the short-interest ratio is presently 10.2 days. Currently, 15.3% of the company's stock are sold short. View Amicus Therapeutics' Current Options Chain.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Beigene (BGNE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Nektar Therapeutics (NKTR), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR) and Catalent (CTLT).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman & CEO (Age 52)
- Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
- Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
- Dr. Jay A. Barth, Chief Medical Officer (Age 55)
- Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $11.99.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.22 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
What is Amicus Therapeutics' official website?
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (NASDAQ FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
